(Q37909351)

25 August 2017

1 reference

title

Emerging drugs for amyotrophic lateral sclerosis (English)

1 reference

amyotrophic lateral sclerosis

25 August 2017

main subject

0 references

2

Hiroshi Mitsumoto

1 reference

25 August 2017

Ali Aamer Habib

1

1 reference

25 August 2017

language of work or name

English

0 references

publication date

1 August 2011

1 reference

Expert Opinion on Emerging Drugs

25 August 2017

published in

1 reference

25 August 2017

volume

16

1 reference

25 August 2017

issue

3

1 reference

25 August 2017

page(s)

537-558

1 reference

Incidence and prevalence of ALS in Ireland, 1995-1997: a population-based study.

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Incidence and prevalence of amyotrophic lateral sclerosis in Uruguay: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Epidemiology of ALS in Italy: a 10-year prospective population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Electrodiagnostic criteria for diagnosis of ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Amyotrophic lateral sclerosis in Sweden, 1991-2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Prognosis in amyotrophic lateral sclerosis: a population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Early symptom progression rate is related to ALS outcome: a prospective population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Energy metabolism in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Prognostic factors in ALS: A critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Outcomes research in amyotrophic lateral sclerosis: lessons learned from the amyotrophic lateral sclerosis clinical assessment, research, and education database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

The syndromes of frontotemporal dysfunction in amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: A population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Recent advances in the genetics of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Mutations of optineurin in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Familial amyotrophic lateral sclerosis is associated with a mutation in D-amino acid oxidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Exome sequencing reveals VCP mutations as a cause of familial ALS

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Chromosome 9p21 in amyotrophic lateral sclerosis in Finland: a genome-wide association study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Excess incidence of ALS in young Gulf War veterans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Occurrence of amyotrophic lateral sclerosis among Gulf War veterans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Prospective study of military service and mortality from ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Neurological mortality among U.S. veterans of the Persian Gulf War: 13-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

ALS in Italian professional soccer players: the risk is still present and could be soccer-specific.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Lower serum lipid levels are related to respiratory impairment in patients with ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

ALS disease onset may occur later in patients with pre-morbid diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from vigibase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Amyotrophic lateral sclerosis-like conditions in possible association with cholesterol-lowering drugs: an analysis of patient reports to the University of California, San Diego (UCSD) Statin Effects Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Statin use and risk of amyotrophic lateral sclerosis and other motor neuron disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Are statin medications safe in patients with ALS?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Genetics of sporadic amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Current hypotheses for the underlying biology of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Prevalence of depressive disorders and change over time in late-stage ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

The economic impact of ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Social economic costs and health-related quality of life in patients with amyotrophic lateral sclerosis in Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

The costs of amyotrophic lateral sclerosis, according to type of care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the Am

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Incidence of amyotrophic lateral sclerosis in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Pivotal studies of orphan drugs approved for neurological diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Clinical trials of orphan medicines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Aggregation and Motor Neuron Toxicity of an ALS-Linked SOD1 Mutant Independent from Wild-Type SOD1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Human Cu/Zn superoxide dismutase (SOD1) overexpression in mice causes mitochondrial vacuolization, axonal degeneration, and premature motoneuron death and accelerates motoneuron disease in mice expressing a familial amyotrophic lateral sclerosis mut

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Wild-type SOD1 overexpression accelerates disease onset of a G85R SOD1 mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Onset and progression in inherited ALS determined by motor neurons and microglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

TDP-43 expression in mouse models of amyotrophic lateral sclerosis and spinal muscular atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

TDP-43 A315T mutation in familial motor neuron disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Rethinking ALS: the FUS about TDP-43.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

A new familial amyotrophic lateral sclerosis locus on chromosome 16q12.1-16q12.2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Two families with familial amyotrophic lateral sclerosis are linked to a novel locus on chromosome 16q.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Two Italian kindreds with familial amyotrophic lateral sclerosis due to FUS mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Analysis of FUS gene mutation in familial amyotrophic lateral sclerosis within an Italian cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Mutations in FUS cause FALS and SALS in French and French Canadian populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

FUS mutations in familial amyotrophic lateral sclerosis in the Netherlands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Juvenile ALS with basophilic inclusions is a FUS proteinopathy with FUS mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

The evidence for altered RNA metabolism in amyotrophic lateral sclerosis (ALS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Selective loss of glial glutamate transporter GLT‐1 in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Expression of the glial glutamate transporter EAAT2 in the human CNS: an immunohistochemical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Excitotoxicity and amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

GluR2 deficiency accelerates motor neuron degeneration in a mouse model of amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Calcium-permeable AMPA receptors promote misfolding of mutant SOD1 protein and development of amyotrophic lateral sclerosis in a transgenic mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Astrocytes regulate GluR2 expression in motor neurons and their vulnerability to excitotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Topiramate protects against motor neuron degeneration in organotypic spinal cord cultures but not in G93A SOD1 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

A double-blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine: effects on CSF glutamate, aspartate, branched-chain amino acid levels and clinical parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Cytochrome c association with the inner mitochondrial membrane is impaired in the CNS of G93A-SOD1 mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Early vacuolization and mitochondrial damage in motor neurons of FALS mice are not associated with apoptosis or with changes in cytochrome oxidase histochemical reactivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Mutant SOD1 from spinal cord of G93A rats is destabilized and binds to inner mitochondrial membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

ALS-associated mutant SOD1G93A causes mitochondrial vacuolation by expansion of the intermembrane space and by involvement of SOD1 aggregation and peroxisomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Mitochondrial respiratory chain dysfunction in muscle from patients with amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Minocycline delays disease onset and mortality in a transgenic model of ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

A randomized sequential trial of creatine in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

A clinical trial of creatine in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Oxidative stress in ALS: a mechanism of neurodegeneration and a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Increased lipid peroxidation in sera of ALS patients: a potential biomarker of disease burden

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Oxidative stress biomarkers in sporadic ALS

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

An increase of oxidized coenzyme Q-10 occurs in the plasma of sporadic ALS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

ER stress and unfolded protein response in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Mutant SOD1 linked to familial amyotrophic lateral sclerosis, but not wild-type SOD1, induces ER stress in COS7 cells and transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

XIAP decreases caspase-12 cleavage and calpain activity in spinal cord of ALS transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Induction of the unfolded protein response in familial amyotrophic lateral sclerosis and association of protein-disulfide isomerase with superoxide dismutase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

ALS-linked mutant SOD1 induces ER stress- and ASK1-dependent motor neuron death by targeting Derlin-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Spinal anterior horn cells in sporadic amyotrophic lateral sclerosis show ribosomal detachment from, and cisternal distention of the rough endoplasmic reticulum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Valproate, a mood stabilizer, induces WFS1 expression and modulates its interaction with ER stress protein GRP94

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Mood stabilizing drug lithium increases expression of endoplasmic reticulum stress proteins in primary cultured rat cerebral cortical cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

A distinctive distribution of reactive astroglia in the precentral cortex in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Innate immunity in amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Wild-Type Nonneuronal Cells Extend Survival of SOD1 Mutant Motor Neurons in ALS Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Integrative role of cPLA with COX-2 and the effect of non-steriodal anti-inflammatory drugs in a transgenic mouse model of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Slowing of axonal transport is a very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

A mutant neurofilament subunit causes massive, selective motor neuron death: implications for the pathogenesis of human motor neuron disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Absence of neurofilaments reduces the selective vulnerability of motor neurons and slows disease caused by a familial amyotrophic lateral sclerosis-linked superoxide dismutase 1 mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Protective effect of neurofilament heavy gene overexpression in motor neuron disease induced by mutant superoxide dismutase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Deregulation of Cdk5 in a mouse model of ALS: toxicity alleviated by perikaryal neurofilament inclusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Riluzole protects against glutamate-induced slowing of neurofilament axonal transport.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

TDP43 is a human low molecular weight neurofilament (hNFL) mRNA-binding protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Neurotrophic factors and neuro-muscular disease: II. GDNF, other neurotrophic factors, and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Neurotrophic factors and neuromuscular disease: I. General comments, the neurotrophin family, and neuropoietic cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Subcutaneous IGF-1 is not beneficial in 2-year ALS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

VEGF protects motor neurons against excitotoxicity by upregulation of GluR2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Expression of hepatocyte growth factor and c-Met in the anterior horn cells of the spinal cord in the patients with amyotrophic lateral sclerosis (ALS): immunohistochemical studies on sporadic ALS and familial ALS with superoxide dismutase 1 gene mu

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Hepatocyte growth factor (HGF) attenuates gliosis and motoneuronal degeneration in the brainstem motor nuclei of a transgenic mouse model of ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Intrathecal delivery of hepatocyte growth factor from amyotrophic lateral sclerosis onset suppresses disease progression in rat amyotrophic lateral sclerosis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Programmed cell death in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Caspase-1 and -3 are sequentially activated in motor neuron death in Cu,Zn superoxide dismutase-mediated familial amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1 mouse model of ALS

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Neuroprotective effects of pramipexole in young and aged MPTP-treated mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Reduction of oxidative stress in amyotrophic lateral sclerosis following pramipexole treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Inhibition by R(+) or S(-) pramipexole of caspase activation and cell death induced by methylpyridinium ion or beta amyloid peptide in SH-SY5Y neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

R+ pramipexole as a mitochondrially focused neuroprotectant: initial early phase studies in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Phase 2 study of sodium phenylbutyrate in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Protection from fatal viral encephalomyelitis: AMPA receptor antagonists have a direct effect on the inflammatory response to infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Talampanel a non-competitive AMPA-antagonist attenuates caspase-3 dependent apoptosis in mouse brain after transient focal cerebral ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Ca(2+)-permeable AMPA receptors and selective vulnerability of motor neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Cytokine upregulation in a murine model of familial amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Circulating levels of tumour necrosis factor-alpha and its soluble receptors are increased in the blood of patients with amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Thalidomide causes sinus bradycardia in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Peroxisome Proliferator-Activated Receptor-gamma in Amyotrophic Lateral Sclerosis and Huntington's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Effects of the PPARgamma activator pioglitazone on p38 MAP kinase and IkappaBalpha in the spinal cord of a transgenic mouse model of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Antisense oligonucleotide therapy for neurodegenerative disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Memantine prolongs survival in an amyotrophic lateral sclerosis mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

A pilot trial of memantine and riluzole in ALS: correlation to CSF biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Bile acids in treatment of ocular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Guidelines for preclinical animal research in ALS/MND: A consensus meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

The occurrence of mutations inFUSin a Belgian cohort of patients with familial ALS

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.604312

10.1517/14728214.2011.604312

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference